Medlive Technology Co., Ltd. (HK:2192) has released an update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Medlive Technology Co., Ltd. has extended its collaboration with M3 to provide digital market research and content services until the end of 2027. This agreement, originally set to expire in 2024, allows Medlive to continue offering specialized digital surveys and tailored content for medical professionals. The transaction is considered a continuing connected transaction under Hong Kong’s listing rules, requiring certain disclosures but not independent shareholder approval.
For further insights into HK:2192 stock, check out TipRanks’ Stock Analysis page.